Invention Grant
- Patent Title: Cancer-treating pharmaceutical composition inhibiting expression of CCND3 or PAK2 gene
-
Application No.: US16346078Application Date: 2017-12-21
-
Publication No.: US10760082B2Publication Date: 2020-09-01
- Inventor: Kyung Hee Koo , Hee Chung Kwon , Jie Young Song
- Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
- Applicant Address: KR Seoul
- Assignee: Korea Institute of Radiological & Medical Sciences
- Current Assignee: Korea Institute of Radiological & Medical Sciences
- Current Assignee Address: KR Seoul
- Agency: Klarquist Sparkman, LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@c1e86ac
- International Application: PCT/KR2017/015260 WO 20171221
- International Announcement: WO2018/124640 WO 20180705
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/04 ; C12N15/113 ; A61P35/00 ; G01N33/68 ; C12Q1/68
Abstract:
A substance inhibiting the expression of CCND3 gene or PAK2 gene, the substance containing a nucleotide such as miR-4779, may be efficiently used for preventing or treating cancer. In addition, by screening the substance that inhibits the expression of CCND3 gene or PAK2 gene, a candidate substance for preventing or treating cancer may be selected.
Public/Granted literature
- US20190256857A1 CANCER-TREATING PHARMACEUTICAL COMPOSITION INHIBITING EXPRESSION OF CCND3 OR PAK2 GENE Public/Granted day:2019-08-22
Information query
